Market Overview

Allergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease

Share:

-- Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily NAMZARIC --

-- NAMZARIC is the only Alzheimer's treatment that contains an NMDA receptor antagonist and an AChEI in a single capsule, a combination that demonstrated greater improvement in cognition and overall function compared to an AChEI alone. --

DUBLIN, July 19, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), today announced that the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC® (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI).

Adamas Pharmaceuticals logo

With the new indication, patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg), can now start combination therapy directly with NAMZARIC.   Approximately 75% of patients diagnosed with Alzheimer's Disease are in the moderate to severe stage of the disease and yet only about one-third of these patients are treated with combination therapy.

"Clinical studies have shown that combination therapy with Namenda XR and an AChEI such as Aricept demonstrated greater improvement in cognition and global function verses an AChEI alone.  NAMZARIC offers the benefits of combining two products that each work differently  to treat moderate to severe Alzheimer's disease while at the same time reducing the number of pills a patient and their caregivers need to administer each day," says Gavin Corcoran, M.D., chief medical officer at Allergan. "At Allergan, we're proud to continue developing products and supporting new programs that can help patients and their caregivers as they navigate this complex disease."

With the new, expanded indication, NAMZARIC will be available in four dosage strengths which allows patients currently taking Aricept 10mg to start on NAMZARIC the very next day. Namzaric is covered broadly by Medicare Part D prescription plans.

In addition to the two currently available dosage strengths, the two new NAMZARIC dosage strengths will be available in pharmacies in September.

For more information about NAMZARIC, visit www.Namzaric.com.

About the Clinical Trial
The efficacy and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), including donepezil HCl, was based on the results of a randomized, double-blind, placebo-controlled trial of 677 patients with moderate to severe Alzheimer's Disease on a stable dose of AChEIs. The clinical study was not conducted with Namazaric; however, bioequivalence of Namzaric with coadministered memantine HCl extended release and donepezil HCl was demonstrated. Approximately 68% of the patients randomized to receive either memantine HCl extended release 28 mg or placebo were taking donepezil as the AchEI at Baseline and throughout the study. The results of this study, demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR (memantine HCl extended release) 28 mg plus an AChEI compared to placebo plus an AchEI at 24 weeks.


About NAMZARIC®
NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil HCl once daily

Memantine hydrochloride extended-release is the active ingredient in the currently marketed NAMENDA XR®, which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Donepezil is the active ingredient in ARICEPT® (donepezil hydrochloride), which is indicated for the treatment of mild to severe dementia of the Alzheimer's type. Allergan and Adamas collaborated on the development of the fixed-dose combination and Allergan owns the exclusive U.S. commercialization rights, while Adamas will retain exclusive commercialization rights outside of the U.S.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
NAMZARIC is contraindicated in patients with known hypersensitivity to memantine hydrochloride,donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation.

WARNINGS AND PRECAUTIONS

Anesthesia
NAMZARIC is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.

Cardiovascular Conditions
NAMZARIC may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block. Bradycardia or heart block may manifest in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil hydrochloride, an active ingredient in NAMZARIC.

Peptic Ulcer Disease and Gastrointestinal Bleeding
Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult
gastrointestinal bleeding, especially those at increased risk for developing ulcers, those with a history of ulcer disease, or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).

Nausea and Vomiting
NAMZARIC can cause diarrhea, nausea, and vomiting. Although in most cases, these effects have been mild and transient, sometimes lasting one to three weeks, and have resolved during continued use of donepezil hydrochloride, patients should be observed closely at the initiation of treatment.

Genitourinary Conditions
NAMZARIC may cause bladder outflow obstructions. Conditions that raise urine pH may decrease the urinary elimination of memantine, an active ingredient in NAMZARIC, resulting in increased plasma levels of memantine.

Seizures
Cholinomimetics, including donepezil hydrochloride, are believed to have some potential to cause generalized convulsions. However, seizure activity also may be a manifestation of Alzheimer's disease.

Pulmonary Conditions
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

ADVERSE REACTIONS

  • The most common adverse reactions, occurring at a frequency of at least 5% in patients taking memantine hydrochloride extended-release 28 mg/day, and greater than placebo, were headache (6% vs 5%), diarrhea (5% vs 4%), and dizziness (5% vs 1%).
  • The most common adverse reactions, occurring at a frequency of at least 5% in patients taking donepezil, and at twice or more the rate of placebo, were diarrhea (10% vs 4%), anorexia (8% vs 4%), vomiting (8% vs 4%), nausea (6% vs 2%), and ecchymosis (5% vs 2%).

DRUG INTERACTIONS

  • Alterations of urine pH toward the alkaline condition may lead to an accumulation of memantine with a possible increase in adverse reactions. NAMZARIC should be used with caution under conditions that may be associated with increased urine pH including alterations by diet, drugs, and the clinical state of the patient.
  • The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.
  • Inhibitors of CYP450, 3A4 (eg, ketoconazole) and 2D6 (eg, quinidine), inhibit donepezil metabolism in vitro. Whether there is a clinical effect of quinidine is not known.
  • Inducers of CYP3A4 (eg, phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil.
  • Cholinesterase inhibitors, including donepezil hydrochloride, have the potential to interfere with the activity of anticholinergic medications.
  • A synergistic effect may be expected when cholinesterase inhibitors, including donepezil hydrochloride, are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.

DOSAGE AND ADMINISTRATION

For patients stabilized on donepezil and not currently on memantine:

For patients stabilized on donepezil hydrochloride 10 mg and not currently on memantine hydrochloride, the recommended starting dose of NAMZARIC is 7 mg/10 mg, taken once a day in the evening. The dose should be increased in 7 mg increments of the memantine hydrochloride component to the recommended maintenance dose of 28 mg/10 mg once daily. The minimum recommended interval between dose increases is one week. The dose should only be increased if the previous dose has been well tolerated. The maximum dose is 28 mg/10 mg once daily.

For patients with severe renal impairment (creatinine clearance 5-29 mL/min, based on the Cockcroft-Gault equation) stabilized on donepezil hydrochloride 10 mg once daily and not currently on memantine hydrochloride the recommended starting dose of NAMZARIC is 7 mg/10 mg taken once a day in the evening. The dose should be increased to the recommended maintenance dose of 14 mg/10 mg once daily in the evening after a minimum of one week.

For patients stabilized on both donepezil and memantine:

Patients stabilized on memantine hydrochloride (10 mg twice daily or 28 mg extended-release once daily) and donepezil hydrochloride 10 mg once daily can be switched to NAMZARIC 28 mg/10 mg, taken once a day in the evening. Patients should start NAMZARIC the day following the last dose of memantine hydrochloride and donepezil hydrochloride administered separately.

Patients with severe renal impairment, stabilized on memantine hydrochloride (5 mg twice daily or 14 mg extended-release once daily) and donepezil hydrochloride 10 mg once daily, can be switched to NAMZARIC 14 mg/10 mg, taken once daily in the evening.

For Full Prescribing Information, visit www.namzaric.com

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

About Adamas
Adamas Pharmaceuticals, Inc. (NASDAQ:  ADMS) is driven to improve the lives of those affected by chronic disorders of the central nervous system.  The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.  Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment.  The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy.  In addition, under a license agreement with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc., the company is eligible to receive royalties from Forest on sales of Namenda XR® and Namzaric™ beginning in June of 2018 and May of 2020, respectively. 

For more information, please visit Adamas's website at www.adamaspharma.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's and Adamas's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's or Adamas's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's and Adamas's  products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended March 31, 2016(certain of such periodic public filings having been filed under the "Actavis plc" name).  Other risks and uncertainties regarding Adamas are detailed in its periodic public filings with the Securities and Exchange Commission, including but not limited to Adamas's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.  Except as expressly required by law, Allergan or Adamas disclaims any intent or obligation to update these forward-looking statements.

                                                                                     

CONTACTS:     Investor: 
                       Allergan 
                      
Lisa Defrancesco
                       (862) 261 7152

             Adamas 
             Julie Wood
             (510) 450 3528                                                                       

                      Media:
                      Allergan
                      Fran DeSena
                      (973) 517-3132

                      Mark Marmur
                      (862) 261-7558

                      Adamas
                     
(510) 450 3567

 

Allergan plc logo

 

Logo - http://photos.prnewswire.com/prnh/20160718/390804LOGO 
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-and-adamas-announce-new-expanded-indication-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease-300300474.html

SOURCE Allergan plc

View Comments and Join the Discussion!